Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.
JAK2(V617F) is the predominant mutation in myeloproliferative neoplasms (MPN). Modeling MPN in a human context might be helpful for the screening of molecules targeting JAK2 and its intracellular signaling. We describe here the derivation of induced pluripotent stem (iPS) cell lines from 2 polycythe...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/485b12392cbc4958a40738009192500c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:485b12392cbc4958a40738009192500c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:485b12392cbc4958a40738009192500c2021-11-18T08:55:05ZHeterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.1932-620310.1371/journal.pone.0074257https://doaj.org/article/485b12392cbc4958a40738009192500c2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24066127/?tool=EBIhttps://doaj.org/toc/1932-6203JAK2(V617F) is the predominant mutation in myeloproliferative neoplasms (MPN). Modeling MPN in a human context might be helpful for the screening of molecules targeting JAK2 and its intracellular signaling. We describe here the derivation of induced pluripotent stem (iPS) cell lines from 2 polycythemia vera patients carrying a heterozygous and a homozygous mutated JAK2(V617F), respectively. In the patient with homozygous JAK2(V617F), additional ASXL1 mutation and chromosome 20 allowed partial delineation of the clonal architecture and assignation of the cellular origin of the derived iPS cell lines. The marked difference in the response to erythropoietin (EPO) between homozygous and heterozygous cell lines correlated with the constitutive activation level of signaling pathways. Strikingly, heterozygous iPS cells showed thrombopoietin (TPO)-independent formation of megakaryocytic colonies, but not EPO-independent erythroid colony formation. JAK2, PI3K and HSP90 inhibitors were able to block spontaneous and EPO-induced growth of erythroid colonies from GPA(+)CD41(+) cells derived from iPS cells. Altogether, this study brings the proof of concept that iPS can be used for studying MPN pathogenesis, clonal architecture, and drug efficacy.Joseph SalibaSofiane HamidiGaëlle LengletThierry LangloisJingkui YinXénia CabagnolsLise SecardinCéline LegrandAnne GalyPaule OpolonBaya BenyahiaEric SolaryOlivier A BernardLongyun ChenNajet DebiliHana RaslovaFrançoise NorolWilliam VainchenkerIsabelle PloAntonio Di StefanoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 9, p e74257 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Joseph Saliba Sofiane Hamidi Gaëlle Lenglet Thierry Langlois Jingkui Yin Xénia Cabagnols Lise Secardin Céline Legrand Anne Galy Paule Opolon Baya Benyahia Eric Solary Olivier A Bernard Longyun Chen Najet Debili Hana Raslova Françoise Norol William Vainchenker Isabelle Plo Antonio Di Stefano Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. |
| description |
JAK2(V617F) is the predominant mutation in myeloproliferative neoplasms (MPN). Modeling MPN in a human context might be helpful for the screening of molecules targeting JAK2 and its intracellular signaling. We describe here the derivation of induced pluripotent stem (iPS) cell lines from 2 polycythemia vera patients carrying a heterozygous and a homozygous mutated JAK2(V617F), respectively. In the patient with homozygous JAK2(V617F), additional ASXL1 mutation and chromosome 20 allowed partial delineation of the clonal architecture and assignation of the cellular origin of the derived iPS cell lines. The marked difference in the response to erythropoietin (EPO) between homozygous and heterozygous cell lines correlated with the constitutive activation level of signaling pathways. Strikingly, heterozygous iPS cells showed thrombopoietin (TPO)-independent formation of megakaryocytic colonies, but not EPO-independent erythroid colony formation. JAK2, PI3K and HSP90 inhibitors were able to block spontaneous and EPO-induced growth of erythroid colonies from GPA(+)CD41(+) cells derived from iPS cells. Altogether, this study brings the proof of concept that iPS can be used for studying MPN pathogenesis, clonal architecture, and drug efficacy. |
| format |
article |
| author |
Joseph Saliba Sofiane Hamidi Gaëlle Lenglet Thierry Langlois Jingkui Yin Xénia Cabagnols Lise Secardin Céline Legrand Anne Galy Paule Opolon Baya Benyahia Eric Solary Olivier A Bernard Longyun Chen Najet Debili Hana Raslova Françoise Norol William Vainchenker Isabelle Plo Antonio Di Stefano |
| author_facet |
Joseph Saliba Sofiane Hamidi Gaëlle Lenglet Thierry Langlois Jingkui Yin Xénia Cabagnols Lise Secardin Céline Legrand Anne Galy Paule Opolon Baya Benyahia Eric Solary Olivier A Bernard Longyun Chen Najet Debili Hana Raslova Françoise Norol William Vainchenker Isabelle Plo Antonio Di Stefano |
| author_sort |
Joseph Saliba |
| title |
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. |
| title_short |
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. |
| title_full |
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. |
| title_fullStr |
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. |
| title_full_unstemmed |
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. |
| title_sort |
heterozygous and homozygous jak2(v617f) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/485b12392cbc4958a40738009192500c |
| work_keys_str_mv |
AT josephsaliba heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT sofianehamidi heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT gaellelenglet heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT thierrylanglois heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT jingkuiyin heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT xeniacabagnols heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT lisesecardin heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT celinelegrand heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT annegaly heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT pauleopolon heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT bayabenyahia heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT ericsolary heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT olivierabernard heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT longyunchen heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT najetdebili heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT hanaraslova heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT francoisenorol heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT williamvainchenker heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT isabelleplo heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients AT antoniodistefano heterozygousandhomozygousjak2v617fstatesmodeledbyinducedpluripotentstemcellsfrommyeloproliferativeneoplasmpatients |
| _version_ |
1718421138154979328 |